Results 151 to 160 of about 63,224 (282)

MDM2 Alters Cellular Iron Homeostasis by Promoting the Degradation of Proteins Involved in Iron Storage and Iron Export. [PDF]

Curr Issues Mol Biol
Shi Y, Zhang J.
europepmc   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Mirror-Peptidizer: In Silico Mirror-Image Screening Enables De Novo Design of D-Peptide Binders without D-Protein Synthesis. [PDF]

Research (Wash D C)
Ma B, Wang Z, Jian Y, Mi Y, Chen S, Hu H, Li X.   +6 more
europepmc   +1 more source

A Three‐Dimensional Culture–Drug Sensitivity Test Predicts MDM2 Inhibitor–Sensitivity in SMARCB1/INI1‐Deficient Tumors

Cancer Science, EarlyView.
This study aimed to determine whether personalized selection of effective drugs for SMARCB1/INI1‐deficient tumors is feasible using in vitro drug sensitivity profiling. Drug sensitivity was assessed using a short‐term collagen gel–embedded three‐dimensional drug sensitivity test (3D‐DST) in tumors derived from SMARCB1/INI1‐deficient tumor cell line ...
Hiroaki Goto, Chiyoko Nishime, Takashi Ohtsu, Mieko Ito, Maiko Sagisaka, Takuya Naruto, Norihiko Kitagawa, Mio Tanaka, Masakatsu Yanagimachi, Yukihiko Hiroshima, Junko Takita, Yasuhide Hayashi, Yohei Miyagi   +12 more
wiley   +1 more source

p53 Pathway-Targeted Therapeutic Strategies in Glioblastoma: A CNS-Specific Framework Integrating Therapeutic Resistance, Molecular Stratification, CNS Pharmacology, and Clinical Translation. [PDF]

Drug Des Devel Ther
Bu F, Zeng S, Ma C, Zhang M.
europepmc   +1 more source

Mdm2 p53 binding protein homolog (MDM2) [PDF]

Science-Business eXchange, 2009
openaire   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

Cancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang, Changyi Fan, Shiheng Chen, Tianyue Lu, Yuanyuan Li, Feng Du, Shanshan Wang   +6 more
wiley   +1 more source

miR-6615-3p-androgen receptor axis modulates granulosa cell fate via the MDM2-p53-BCL2 pathway in hen Prehierarchical follicles. [PDF]

Poult Sci
Zhang D, Xu Z, Zhou YY, Qian W, Ahmadi S, Xu R, Zhang S, Qin N, Sun X.   +8 more
europepmc   +1 more source

Ploidy‐Dependent Response to Anticancer Drugs of Human Embryonic Stem Cells

Cell Proliferation, EarlyView.
Using isogenic hESCs, differing only in their ploidy level, we show the effect of ploidy on the resistance to anticancer drugs. We demonstrate that polyploidy, by itself, confers sensitivity to chemotherapies, leading to higher apoptosis and delayed proliferation, while the loss of p53 reverses the phenotype, demonstrating higher resistance.
Guy Haim‐Abadi, Nissim Benvenisty
wiley   +1 more source

Glioma-associated oncogene homolog 1-altered mesenchymal tumour of the upper oesophageal sphincter. [PDF]

BMJ Case Rep
Hebert S, Peters M, Cuevas-Ocampo A, Dewan K.   +3 more
europepmc   +1 more source